[Dermatologic toxicity to sorafenib].
Velázquez
D
D
de la Cueva
P
P
Zamberk
P
P
Lázaro
P
P
D000970:Antineoplastic Agents / Q000633:toxicity*; D001557:Benzenesulfonates / Q000633:toxicity*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000633:toxicity*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib